The NASH curse strikes again. Pfizer dumps early-stage asset for liver condition Takeda cuts ties to cancer drug landed in $120M Turnstone deal Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant Sponsored: Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb Reports of DOJ probe into Cassava 'old news in new fish wrapper,' CEO says Months after formation, Spexis narrows focus to keep lights on into 2023 Elevation Oncology sets out for clinic climb in $27M licensing deal for CSPC's ADC Labcorp to splice off clinical development arm into standalone business Nothing to Seagen here: Merck remains mum on merger New drug could flip the script for stroke treatment, but small Canadian biotech needs funding boost Velocity Clinical Research buys site in Germany, marking EU expansion City of Hope's new 'comprehensive' cancer center boasts cutting-edge research, treatments and a full-service salon GSK, still early in US launch, licenses long-acting HIV PrEP drug Apretude to patent pool for poorer nations Featured Story | By James Waldron Another NASH drug bites the dust. This time it’s Pfizer’s early-stage asset danuglipron, which the drugmaker revealed this morning had been dumped for the liver condition. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Takeda is walking away from a cancer prospect it picked up in a $120 million deal. In a pipeline clear-out that also hit narcolepsy candidate TAK-994, the Japanese drugmaker revealed it has returned the rights to oncolytic virus TAK-605 to Turnstone Biologics just 31 months after inking a deal for the drug. read more By Annalee Armstrong Patients with kidney disease taking Ionis Pharmaceuticals and Bayer’s anti-thrombotic therapy did not experience an increase in major bleeding events as compared to those taking placebo, meaning patients may someday have a new anticoagulant option that does not come with a risk of bleeding. read more Sponsored by: PathAI Learn how Bristol Myers Squibb is unlocking new insights in translational research and development by transforming pathology with artificial intelligence. read more By Annalee Armstrong Cassava Sciences CEO Remi Barbier called reports of a new Department of Justice criminal investigation into the Alzheimer’s disease biotech’s scientific practices “old news in [a] new fish wrapper.” read more By Nick Paul Taylor Spexis has run into trouble just months after its formation. With the ink barely dry on the merger that created it, the Swiss biotech is narrowing its focus to stretch its cash runway out to January 2023. read more By Gabrielle Masson Elevation Oncology is setting out for a climb to the clinic, with $27 million paid out in a new licensing deal for an antibody drug conjugate (ADC) from CSPC Megalith Biopharmaceutical. read more By Max Bayer Labcorp will spin off its clinical development arm into its own company, a departure from a decision at the end of 2021 to maintain the corporate structure. The deal is expected to close in the second half of next year. read more By Kevin Dunleavy Without a single word in its press release about Seagen—the powerful biotech it has reportedly been targeting for a buyout over the last several weeks—Merck revealed second-quarter earnings that showed exactly why the top-heavy company is so anxious to make a transformational deal. With Keytruda generating $5.3 billion in the second quarter, the versatile cancer juggernaut accounted for 36% of the company’s revenue figure of $14.6 billion. read more By Gabrielle Masson A new drug may be able to protect and repair damage caused by stroke up to a week after onset, though limited resources may block the path to clinic. read more By Gareth Macdonald Europe is the key to clinical trial recruitment success, says site organization Velocity Clinical Research, which has acquired a clinical research location in Hamburg, Germany. read more By Dave Muoio The organization's newly opened facility boasts cutting-edge research, treatments and a full-service salon for patients. read more By Angus Liu Antivirals have historically made up the bulk of licenses that allow generics companies to copy innovative drugs for poorer countries. Now, GSK’s ViiV Healthcare is adding the world’s first long-acting HIV prevention med to a patent-sharing program merely seven months into an FDA approval. read more Resources Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Lumanity Join us, as we explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene therapy space. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 